DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome

被引:102
作者
Fisel, Pascale [1 ,2 ]
Kruck, Stephan [3 ]
Winter, Stefan [1 ,2 ]
Bedke, Jens [3 ]
Hennenlotter, Joerg [3 ]
Nies, Anne T. [1 ,2 ]
Scharpf, Marcus [4 ]
Fend, Falko [4 ]
Stenzl, Arnulf [3 ]
Schwab, Matthias [1 ,2 ,5 ]
Schaeffeler, Elke [1 ,2 ]
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Univ Tubingen Hosp, Dept Urol, Tubingen, Germany
[4] Univ Tubingen Hosp, Inst Pathol & Neuropathol, Tubingen, Germany
[5] Univ Tubingen Hosp, Dept Clin Pharmacol, Tubingen, Germany
关键词
CELL CARCINOMA; KIDNEY CANCER; SURVIVAL; METABOLISM; MUTATIONS; HYPOXIA; PBRM1; RISK; BAP1;
D O I
10.1158/1078-0432.CCR-13-1180
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: The monocarboxylate transporter 4 (MCT4) is a metabolic target in tumor biology because it mediates lactate transport across membranes resulting in antiapoptotic effects. Cell experiments support the importance of MCT4 in clear cell renal cell carcinoma (ccRCC). In this study, we assessed the prognostic potential of MCT4 expression in ccRCC and its epigenetic regulation by DNA methylation as novel predictive marker for patient outcome using independent ccRCC cohorts. Experimental Design: MCT4 protein expression was quantified in 207 ccRCC and corresponding nontumor tissues. Data of an independent ccRCC cohort from The Cancer Genome Atlas (TCGA) were analyzed on MCT4 mRNA (n = 482) and DNA methylation (n = 283) level. The findings on MCT4 expression and DNA methylation in the SLC16A3 promoter were validated in a third cohort (n = 64). Promoter activity assays were conducted in four RCC cell lines. Results: MCT4 protein expression was upregulated (P < 0.0001) in ccRCC and showed significant association with cancer-related death. Upregulation of MCT4 mRNA expression (P < 0.00001) was confirmed in the TCGA cohort. Single CpG sites correlated inversely with mRNA expression and were associated with overall survival in Kaplan-Meier analyses [HR = 0.39; 95% confidence interval (CI), 0.24-0.64; P[log-rank] = 1.23e(-04)]. Promoter activity studies confirmed MCT4 regulation by DNA methylation. The significant correlation between MCT4 protein and gene expression or DNA methylation at single CpG sites was validated in a third cohort. Again, higher methylation at individual CpG sites was associated with prolonged survival [HR = 0.05; 95% CI, 0.01-0.40; P[log-rank] = 6.91e(-05)]. Conclusion: We identified SLC16A3 promoter DNA methylation as a novel epigenetic mechanism for MCT4 regulation in ccRCC with first evidence of a biological rationale for prognosis and clinical outcome. (C) 2013 AACR.
引用
收藏
页码:5170 / 5181
页数:12
相关论文
共 31 条
[1]
Al-Aynati M, 2003, ARCH PATHOL LAB MED, V127, P593
[2]
[Anonymous], 2012, R LANG ENV STAT COMP
[3]
Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia [J].
Claus, Rainer ;
Lucas, David M. ;
Stilgenbauer, Stephan ;
Ruppert, Amy S. ;
Yu, Lianbo ;
Zucknick, Manuela ;
Mertens, Daniel ;
Buehler, Andreas ;
Oakes, Christopher C. ;
Larson, Richard A. ;
Kay, Neil E. ;
Jelinek, Diane F. ;
Kipps, Thomas J. ;
Rassenti, Laura Z. ;
Gribben, John G. ;
Doehner, Hartmut ;
Heerema, Nyla A. ;
Marcucci, Guido ;
Plass, Christoph ;
Byrd, John C. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2483-2491
[4]
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development [J].
Duns, Gerben ;
Hofstra, Robert M. W. ;
Sietzema, Jantine G. ;
Hollema, Harry ;
van Duivenbode, Inge ;
Kuik, Angela ;
Giezen, Cor ;
Osinga, Jan ;
Bergsma, Jelkje J. ;
Bijnen, Harrie ;
van der Vlies, Pieter ;
van den Berg, Eva ;
Kok, Klaas .
HUMAN MUTATION, 2012, 33 (07) :1059-1062
[5]
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target [J].
Gerlinger, Marco ;
Santos, Claudio R. ;
Spencer-Dene, Bradley ;
Martinez, Pierre ;
Endesfelder, David ;
Burrell, Rebecca A. ;
Vetter, Marcus ;
Jiang, Ming ;
Saunders, Rebecca E. ;
Kelly, Gavin ;
Dykema, Karl ;
Rioux-Leclercq, Nathalie ;
Stamp, Gordon ;
Patard, Jean Jacques ;
Larkin, James ;
Howell, Michael ;
Swanton, Charles .
JOURNAL OF PATHOLOGY, 2012, 227 (02) :146-156
[6]
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network [J].
Hakimi, A. Ari ;
Ostrovnaya, Irina ;
Reva, Boris ;
Schultz, Nikolaus ;
Chen, Ying-Bei ;
Gonen, Mithat ;
Liu, Han ;
Takeda, Shugaku ;
Voss, Martin H. ;
Tickoo, Satish K. ;
Reuter, Victor E. ;
Russo, Paul ;
Cheng, Emily H. ;
Sander, Chris ;
Motzer, Robert J. ;
Hsieh, James J. .
CLINICAL CANCER RESEARCH, 2013, 19 (12) :3259-3267
[7]
HOLM S, 1979, SCAND J STAT, V6, P65
[8]
State of the Science: An Update on Renal Cell Carcinoma [J].
Jonasch, Eric ;
Futreal, P. Andrew ;
Davis, Ian J. ;
Bailey, Sean T. ;
Kim, William Y. ;
Brugarolas, James ;
Giaccia, Amato J. ;
Kurban, Ghada ;
Pause, Armin ;
Frydman, Judith ;
Zurita, Amado J. ;
Rini, Brian I. ;
Sharma, Pam ;
Atkins, Michael B. ;
Walker, Cheryl L. ;
Rathmell, W. Kimryn .
MOLECULAR CANCER RESEARCH, 2012, 10 (07) :859-880
[9]
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation [J].
Kapur, Payal ;
Pena-Llopis, Samuel ;
Christie, Alana ;
Zhrebker, Leah ;
Pavia-Jimenez, Andrea ;
Rathmell, W. Kimryn ;
Xie, Xian-Jin ;
Brugarolas, James .
LANCET ONCOLOGY, 2013, 14 (02) :159-167
[10]
Hyperpolarized 13C-Pyruvate Magnetic Resonance Reveals Rapid Lactate Export in Metastatic Renal Cell Carcinomas [J].
Keshari, Kayvan R. ;
Sriram, Renuka ;
Koelsch, Bertram L. ;
Van Criekinge, Mark ;
Wilson, David M. ;
Kurhanewicz, John ;
Wang, Zhen J. .
CANCER RESEARCH, 2013, 73 (02) :529-538